Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users.
about
Pneumococcal vaccine for preventing Streptococcus pneumoniae infection in HIV-infected individualsProduction of IgG antibodies to pneumococcal polysaccharides is associated with expansion of ICOS+ circulating memory T follicular-helper cells which is impaired by HIV infection.Pneumococcal Vaccination Strategies. An Update and Perspective.Polycyclic aromatic hydrocarbons and cytochrome P450 in HIV pathogenesis.Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.Bloodstream infections in HIV-infected patients.Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects.Antiretroviral Therapy as Prevention of … Pneumococcal Infections?Risk factors for community-acquired bacterial meningitis.Immunization of HIV-infected adult patients - French recommendations.Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.Antibody Response is More Likely to Pneumococcal Proteins Than to Polysaccharide After HIV-associated Invasive Pneumococcal Disease.Pathogenesis of infections in HIV-infected individuals: insights from primary immunodeficiencies.Pharmacokinetics and Pharmacodynamic Target Attainment of Benzylpenicillin in an Adult Severely ill Sub-Saharan African Patient Population.Adverse events after vaccination among HIV-positive persons, 1990-2016.
P2860
Q24186767-6A017AE5-D10E-44D9-A5A1-B38361FDD958Q33626626-CF88BB48-F1FD-407A-B3C8-A30A4805FB45Q33772409-1AF4F395-DFB5-4EB3-8004-B98C33F38330Q35672088-EFE1848D-61D2-4F87-86BB-919E393A2012Q36523805-742977CA-DA74-4EBD-A6DB-33B2B5D81738Q36913307-0D44C229-30B8-4527-AFB6-03098C173178Q37197130-D00811FF-B512-4113-B499-F69E2E3F343EQ37518007-8E417B95-B953-4E16-966B-A0363DF3338FQ39182388-70C1DC3C-D999-4D93-9DA2-5447E8BD15FBQ40615516-E62FC935-1E14-4EF0-8BEB-F98F436733C5Q41007698-0339ADE3-A36D-4CD7-8EB9-98E2ABCB8AE3Q41436543-B67566EA-E94C-43C6-A62D-C469972D2000Q41989467-E06B736A-2EA9-40B6-B70A-FEFA9C3BF968Q46545782-6BAB514B-BA6D-45D2-AD27-1D6B6D229948Q55347685-A6ECBE80-C357-4068-8A4D-6EB3C22BFB42
P2860
Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Incidence and risk factors for ...... infected injecting drug users.
@en
type
label
Incidence and risk factors for ...... infected injecting drug users.
@en
prefLabel
Incidence and risk factors for ...... infected injecting drug users.
@en
P2093
P2860
P50
P356
P1476
Incidence and risk factors for ...... infected injecting drug users.
@en
P2093
Carsten Schade Larsen
Court Pedersen
Gitte Kronborg
Gitte Pedersen
Helle Bossen Konradsen
Jan Gerstoft
Mette Vang Larsen
Zitta Barrella Harboe
P2860
P304
P356
10.1093/CID/CIU558
P407
P577
2014-07-17T00:00:00Z